Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTIS2022-502348-11-00
CTIS2022-502348-11-00RecruitingPhase 1

SGNBB228-001

Seagen Inc.0 sites275 target enrollmentStarted: April 14, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Enrollment
275
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 65+ (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Similar Trials

Recruiting
Phase 1
First-in human, dose escalation and cohort expansion study for the evaluation of LB-208 (HTR1B antagonist) in adult patients with relapsed or refractory solid tumours and lymphomaymphoma, Solid tumorMedDRA version: 20.0Level: HLGTClassification code: 10025323Term: Lymphomas NEC Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104
CTIS2023-509532-25-00eukos Biotech S.L.42
Recruiting
Phase 1
A Study of NB003 in Patients With Advanced Malignancies
CTIS2022-502401-15-00ingbo Newbay Technology Development Co. Ltd.290
Active, not recruiting
Phase 1
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune ThrombocytopeniaPrimary immune thrombocytopenia (ITP)MedDRA version: 23.0Level: PTClassification code: 10083842Term: Immune thrombocytopenia Class: 100000004851
CTIS2023-508819-23-00Hutchmed Ltd.51
Active, not recruiting
Phase 1
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.MedDRA version: 20.1Level: LLTClassification code: 10054109Term: Non-proliferative diabetic retinopathy Class: 10015919MedDRA version: 23.1Level: PTClassification code: 10064848Term: Chronic kidney disease Class: 100000004857Chronic kidney disease
CTIS2024-510856-11-00Bayer AG15
Recruiting
Phase 1
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER
CTIS2023-508058-24-01ovImmune S.A.12